In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

Druckenmiller wasn't the only big investor to pick up Tesla shares last quarter, with hedge-fund giant Bridgewater also buying into the Elon Musk car company, which rose 62% last year thanks to a ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.